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Rika Sakai,1 Heiwa Kanamori,2 Kenji Motohashi,2 Wataru Yamamoto,1 Shiro Matsuura,1
Atsuko Fujita,1 Rika Ohshima,1 Hideyuki Kuwabara,1 Masatsugu Tanaka,2 Hiroyuki Fujita,3
Atsuo Maruta,2 Yoshiaki Ishigatsubo,3 Shin Fujisawa1Human herpesvirus-6 (HHV-6) encephalitis is recognized as a relatively rare, but sometimes lethal, compli-
cation of allogeneic hematopoietic stem cell transplantation (HSCT). Although the development of new
diagnostic techniques and antiviral therapy has improved, the prognosis of encephalitis is still unclear. We
surveyed 197 patients who underwent allogeneic HSCT between January 2004 and March 2008 at our insti-
tution, and 8 (4.0%) were diagnosed as having HHV-6 encephalitis. Five were male and 3 were female, with
a median age of 40.5 years. The median onset of HHV-6 encephalitis was 18 days after HSCT, and the median
duration of antiviral therapy was 41 days. The median survival time from the onset of encephalitis was 23.1
months (range: 2.7-66.7), and 3 patients died of unrelated causes (sepsis in 2 and gastrointestinal tract
bleeding in 1). Cord blood transplantation was identified as the only independent risk factor (relative risk
[RR] 5 4.98; P 5 .049) by multivariate analysis. There was no statistical significance of survival after
HSCT between the patients with HHV-6 encephalitis and those without HHV-6 encephalitis (the 2-year
survival rate was 60% and 52.6%, respectively; P 5 .617). Four of the 5 surviving patients were unable to
return to society because of neuropsychological disorders, including anterograde amnesia and seizures
with prominent hippocampal atrophy. Although HHV-6 encephalitis occurring after HSCT is now becoming
a curable complication, its sequelae, such as neuropsychological disorders, have a marked influence on the
quality of life of long-term survivors. Accordingly, it is necessary to identify risk factors for HHV-6 enceph-
alitis and establish methods for prevention of this complication.
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of lifeINTRODUCTION
Primary HHV-6 infection typically occurs at the
age of 6 to 12 months [1], and HHV-6 can persist in
the host after infection like the other human herpesvi-
ruses [2]. ReactivationofHHV-6 is frequently detected
in immunosuppressed patientswho receive hematopoi-
etic stem cell transplantation (HSCT) and has been1Department of Hematology, Yokohama City University
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6/j.bbmt.2011.01.014suggested to be associated with an increase of severe
clinicalmanifestations, including graft-versus-host dis-
ease (GVHD), and/ormortality after allogeneicHSCT
[3,4]. It has been demonstrated that there is an
association between HHV-6 infection and posttrans-
plant fatal limbic encephalitis [3,5-7], but few patients
actually develop HHV-6–associated encephalitis after
HSCT, and the sequelae of such encephalitis in survi-
vors have not been fully investigated. To clarify the
neuropsychological disorders in survivors with HHV-
6 encephalitis, we retrospectively investigated the out-
come of HHV-6 encephalitis after allogeneic HSCT.PATIENTS AND METHODS
The study population consisted of 197 patients
who underwent allogeneicHSCT for hematologic dis-
orders between January 2004 andMarch 2008 at Yoko-
hama City University Medical Center or Kanagawa
Cancer Center. The recipients received cyclosporine
or tacrolimus with or without short-termmethotrexate1389
1390 Biol Blood Marrow Transplant 17:1389-1394, 2011R. Sakai et al.for the prevention of GVHD. All recipients received
acyclovir after HSCT to prevent herpes simplex virus
infection. The time of neutrophil engraftment was de-
fined as the first of 3 consecutive days with a neutrophil
count.500 cells/mL.HHV-6 encephalitis was defined
as the occurrence of unexplained neuropsychological
disorders associated with a positive quantitative poly-
merase chain reaction (PCR) for HHV-6 in the cere-
brospinal fluid (CSF).
A real-time quantitative PCR assay forHHV-6was
performed using the LightCycler FastStart DNA
Master Hybridization Probes kit (Roche Diagnostics,
Mannheim, Germany), as described previously [8].
The sequences of the forward primer was 50-AC
CCGAGAGATGATTTTGCG-30 and the reverse
primer was 50-GCAGAAGACAGCAGCGCGAT-30.
A fluorescein probe (50-TAAGTAACCGTTTTC
GTCCCA-30) and a 50-LCRed640–labeled probe (50-
GGGTCATTTATGTTATAGACGGT-30) were lo-
cated between the primers. Viral reactivation was
defined as the detection of at least 1 copy of viral
DNA in plasma (25 copies/mL plasma).
Patients who had unexplained neuropsychological
disorders without CSF data were excluded from this
study. Detailed clinical information was collected by
reviewing medical records at both hospitals. Follow-
up of the surviving patients was performed until
November 30, 2009.Statistical Analysis
To determine an independent risk factor for devel-
oping HHV-6 encephalitis, we performed Cox pro-
portional hazards analysis including the following
variables: recipient age and sex, disease risk (standard-
risk diseases were acute leukemia in the first or second
complete remission [CR], aplastic anemia, refractory
anemia, refractory anemia with ringed sideroblasts,
chronic myeloid leukemia [CML] in the first chronic
phase [CP], and malignant lymphoma [ML] in the first
or second CR, whereas all other diseases/states were
considered to be high risk), stem cell source (bone
marrow [BM] or peripheral blood stem cells [PBSC]
from a related donor, BM from an unrelated donor,
and cord blood [CB] from an unrelated donor; there
were no PBSC from unrelated donors), conditioning
regimen (conventional versus reduced intensity), use
of total-body irradiation (TBI), and GVHD prophy-
laxis (cyclosporine based versus tacrolimus based).
Survival curves after HSCT were estimated by the
Kaplan-Meier method, and the survival of patients
with HHV-6 encephalitis was compared with that of
those without HHV-6 encephalitis by the log-rank
test, treating the occurrence of HHV-6 encephalitis
as a time-dependent variable. Statistical analyses
were performed with SPSS Software (SPSS Inc.,
Chicago, IL).RESULTS
Baseline Characteristics of the Patients
with HHV-6 Encephalitis
Among 197 patients who underwent allogeneic
HSCT, 8 (4.0%) were diagnosed as havingHHV-6 en-
cephalitis. Two patients had unexplained neuropsy-
chological disorders without CSF data, and these
patients were excluded from the study. No patient
was treated with ex vivo or in vivo T cell depletion.
Five were men and 3 were women, with a median age
of 40.5 years (range: 22-57 years). The underlying dis-
ease was acute myeloid leukemia (AML) in 3 patients
and acute lymphoblastic leukemia (ALL) in 5 patients.
Six patients were in remission at the time ofHSCT. All
of them received stem cells from unrelated donors, in-
cluding 4 with CB transplantation. Only 1 patient
received BM from an HLA-matched unrelated donor,
whereas the others received BM from DR-
mismatched unrelated donor (n 5 1) or DRB1-
mismatched unrelated donors (n 5 2). Myeloablative
conditioning was carried out in all but 1 patient. For
GVHD prophylaxis, all CB recipients received tacroli-
mus alone and the others received tacrolimus plus
short-term methotrexate. All of the patients achieved
neutrophil engraftment. The median time until
engraftment was 16 days (range: 13-70 days) after
HSCT. One patient was treated with gancyclovir for
HHV-6 encephalitis before neutrophil engraftment,
which was delayed until day 70. Six out of 8 patients de-
veloped acute GVHD (aGVHD) (grade I in 1 and
grade III in 5) before and after the diagnosis of
HHV-6 encephalitis. Five patients received predniso-
lone, and 4 of them showed a good response (3 had
complete remission and 1 had partial remission) to
treatment by established criteria [9] (Table 1).
CB stem cell transplantation was identified as an
independent risk factor (relative risk [RR], 4.98; P 5
.049) by multivariate analysis (Table 2). The percent-
age of patients receiving related BM, unrelated BM,
PBSC, and CB among the HHV6-encephalitis pa-
tients was 0%, 50%, 0%, and 50%, respectively,
whereas among the other patients, the percentage
was 27.5%, 37%, 14.8%, and 20.6%, respectively.Clinical Presentation of HHV-6 Encephalitis
and Outcome of Treatment
Table 1 shows the clinical presentation and out-
come of the patients with HHV-6 encephalitis. The
median onset was 18 days after HSCT (range: 8-27
days). All patients had high fever and the acute onset
of severe anterograde amnesia with confusion. Gener-
alized seizures also occurred in 2 patients. Patient 7
initially complained of the sudden onset of severe
bilateral lower limb pain, which resembled calcineurin
inhibitor–induced pain syndrome [10], followed by
Table 1. Clinical Presentation and Outcome of the Patients with HHV-6 Encephalitis
Symptoms Response to Antiviral Treatment
Patient
HSCT-HHV6
Encephalitis
Interval
(Days) Fever
Amnesia/
Confusion Seizures
CSF HHV6
PCR
(Copies/mL)
Focal
Hyperintensities
on MRI
Onset of
aGVHD
(Days)
Maximum
Grade of
aGVHD
Treatment
with PSL for
aGVHD at
the Onset of
Encephalitis
Antiviral
Treatment
(Days after
Transplantation)
CSF HHV6
PCR
Neuropsychological
disorders
Outcome
(Days after
the Onset
of HHV6
Encephalitis)
Cause of
Death
1 27 + + — 590 lt medial
temporal lobe
8 III yes ganciclovir
(26-68)
negative Good cognitive recovery Alive (2001)
2 15 + + — 89,500 hippocampus — — no ganciclovir
(15-53)
negative Poor cognitive recovery
with somnolence
Dead (82) Sepsis
3 21 + + — 8840 cerebellum 23 III no foscarnet
(21-77)
negative Good cognitive recovery Dead (139) Pneumonia
4 14 + + — 5600 uncus/amygdala/
hippocampus
50 I no ganciclovir
(14-51)
negative Modest cognitive recovery
with persistent episodic
memory impairment
Alive (1679)
5 15 + + + 199,000 hippocampus/
occipital lobe
— — no foscarnet
(16-31)
negative Modest cognitive recovery
with persistent episodic
memory impairment and
generalized seizures
Alive (807)
6 19 + + + 84,400 hippocampus 13 III yes foscarnet
(20-40)
negative Poor cognitive recovery
with persistent episodic
memory impairment
and lack of motivation
Dead (327) cGVHD/
gastrointestinal
bleeding
7 20 + + — 930,000 uncus/amygdala/
hippocampus
12 III yes ganciclovir/
foscarnet
(20-82/83-96)
negative Modest cognitive recovery
with persistent episodic
memory impairment
Alive (627)
8 15 + + — 130,000 uncus/amygdala/
hippocampus
26 III no foscarnet/
ganciclovir
(15-20/21-80)
negative Modest cognitive recovery
with persistent episodic
memory impairment
Alive (758)
CSF indicates cerebrospinal fluid; PCR, polymerase chain reaction; MRI, magnetic resonance image; PSL, prednisolone; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease.
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Table 2. Multivariate Analysis of Factors Related to HHV-6
Encephalitis
Variable RR (95% CI) P Value
Donor source, CB 4.98 1.009-24.583 .049
CB indicates cord blood; RR, relative risk; CI, confidence interval.
Figure 1. Kaplan-Meier curves for overall survival after HSCT in pa-
tients with or without HHV-6 encephalitis. — HHV-6 encephalitis (1)
(n5 8); ————HHV-6 encephalitis (2) (n5 189). There was no sta-
tistical significance of survival between the patients with HHV-6 enceph-
alitis and those without it (P 5 .617).
1392 Biol Blood Marrow Transplant 17:1389-1394, 2011R. Sakai et al.disturbance of consciousness. Examination of CSF at
the onset of encephalitis revealed a median of 84,400
copies/mL of HHV-6 DNA (range: 590-930,000). In
6 patients, magnetic resonance imaging (MRI) with
the fluid attenuation inversion recovery (FLAIR) se-
quence demonstrated hyperintensities in the hippo-
campus at the onset of encephalitis. MRI also
revealed hyperintensities on FLAIR sequences in the
left medial temporal lobe of patient 1 and in the cere-
bellum of patient 3.
Three patients developed HHV-6 encephalitis af-
ter starting treatment for aGVHD. Four patients
were initially treated with ganciclovir, and the others
received foscarnet. None of them had received ganci-
clovir or foscarnet previously. The median duration
of antiviral therapy was 41 days (range: 16-77 days). Al-
though PCR of the CSF for HHV-6 was negative by
the end of antiviral therapy in all patients, only 2 pa-
tients showed good cognitive recovery, and the others
had modest or poor cognitive recovery with persistent
impairment of episodicmemory and lack ofmotivation
or generalized seizures. Themedian survival time from
the onset of encephalitis was 23.1 months (range: 2.7-
66.7 months). Three patients died of causes unrelated
to HHV-6 encephalitis (sepsis on day 97, pneumonia
on day 160, and gastrointestinal tract bleeding associ-
ated with chronic GVHD (cGVHD) on day 345 after
HSCT, respectively). The overall survival (OS) rate
at both 1 year and 3 years after the onset of HHV-6 en-
cephalitis was 62.5 6 17.1% by the Kaplan-Maier
method. There was no statistical significance of sur-
vival after HSCT between the patients with HHV-6
encephalitis and those without it (the 2-year survival
rate was 60% and 52.6%, respectively; P 5 .617;
Figure 1).
Symptoms of HHV-6 Encephalitis Survivors at
Final Follow-Up
Table 3 shows a summary of the symptoms of 5
survivors on the last day of follow-up. The perfor-
mance status of the patients (Eastern Cooperative On-
cology Group [ECOG] criteria) showed a wide range.
Four patients were in continuing remission, and the
others were in second remission following systemic
chemotherapy for relapse after HSCT. Two patients
had cGVHD without systemic immunosuppressive
treatment. Four patients had persistent episodic mem-
ory impairment, 3 were lethargic, and 2 had persistent
modest joint contracture andmuscle weakness. Patient
7 developed severe idiopathic peripheral polyneurop-athy of both lower limbs, with a performance status
of 4. Four out of 5 survivors were unable to return to
school/work or social life because of persistent neuro-
psychological disorders at the end of follow-up.
Figure 2 shows changes over time on FLAIR images
in patient 7, which demonstrated hyperintensities in
the bilateral hippocampus during the early subacute
phase after the onset of HHV-6 encephalitis and
prominent hippocampal atrophy in the late phase (40
and 221 days). FLAIR images of another 2 patients
(patients 4 and 8) also showed hippocampal hyperin-
tensities during the early phase and atrophy during
the late phase of HHV-6 encephalitis.
DISCUSSION
The reactivation of HHV-6 is now recognized to
be relatively common after HSCT and is associated
with serious transplantation-related morbidity and
mortality [3,4]. CB transplantation was extracted as
the only risk factor for HHV-6 encephalitis in this
study. Sashihara et al. [11] suggested the possibility
that CB transplantationmight be a risk factor for active
HHV-6 infection and HHV-6 RT-PCR revealed
a higher level of viral DNA in CB transplantation re-
cipients than in BM/PBSC transplantation recipients.
Yamane et al. [7] also reported that CB transplantation
was 1 of the risk factors for HHV-6 reactivation after
allogeneic HSCT, and that HHV-6 DNAemia was
associated with HHV-6 encephalitis after allogeneic
HSCT. In the prospective study of Zerr et al.,
HHV-6 reactivation was observed in 47% of 110 adult
patients and was significantly associated with severe
(grade III-IV) GVHD and all-cause mortality [3]. In
our study, 5 out of 8 patients with HHV-6 encephalitis
had severe aGHVD before or after the diagnosis of en-
cephalitis. The cause of death in all 3 patients after the
onset of HHV-6 encephalitis was associated with
GVHD and/or treatment-related infections.
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Biol Blood Marrow Transplant 17:1389-1394, 2011 1393Long-Term Outcome of Human Herpesvirus-6 Encephalitis after HSCTIt is well known that severe aGVHD is associated
with a high treatment-relatedmortality after allogeneic
HSCT [12]. Some reports have also indicated that pa-
tients who develop HHV-6 encephalitis after HSCT
have a poor prognosis, with the direct cause of death be-
ing progressive encephalitis or aGVHD and infection
[13-15]. Fujimaki et al. [13] reported 11 patients with
HHV-6 encephalitis among 1148 recipients of alloge-
neic HSCT between 1999 and 2003 in a retrospective
multicenter study; their median survival was signifi-
cantly reduced (57 days after HSCT), and 8 of them
died of encephalitis (n 5 3) or GVHD/infection (n 5
5). Zerr [14] reviewed the data on 48 HSCT recipients
withHHV-6 encephalitis: among 44 patients for whom
information on the neurologic course and outcomewas
available, 19 patients (43%) showed full recovery, 8
(18%) had neurologic sequelae, 6 (14%) died ofmedical
problems unrelated to encephalitis, and 11 (23%)
showed a progressive course and died of encephalitis.
Review of case reports and retrospective studies may
not accurately reflect the general clinical features of
HHV-6 encephalitis, but these reports still indicate
that the outcome ofHHV-6 encephalitis is poor. Com-
pared with these reports, our retrospective study
showed a slight improvement of the prognosis. The re-
cent development of diagnostic methods and antiviral
therapy for HHV-6 encephalitis, as well as better man-
agement of GVHD and infection, may have improved
survival in patients with HHV-6 encephalitis after
HSCT. Nevertheless, only 1 of our patients could fully
return to society among 5 survivors of HHV-6 enceph-
alitis. The remaining patients had various persistent
neuropsychological disorders even at 1 year or more
after HSCT. In the patients who could not return to
society, MRI showed prominent hippocampal atrophy
during the late phase ofHHV-6 encephalitis. These re-
sults suggest that some of the effects ofHHV-6 enceph-
alitis, especially in relation to the limbic system, can be
irreversible and cause impairment of the quality of life.
Prevention of HHV-6 encephalitis is the most impor-
tant strategy in this setting. Two small, nonrandomized
studies of HSCT recipients have suggested that pro-
phylactic administration of ganciclovir can prevent
HHV-6 reactivation [16-18]. However, it is difficult
to always use ganciclovir for prevention after HHV-6
reactivation after HSCT because of severe myelosup-
pression in some patients. Foscarnet is active against
HHV-6 both in vitro and in vivo [19,20], but this
agent can also be difficult to use for HSCT recipients
because there is a risk of severe nephrotoxicity at
therapeutic dose levels [21]. In our retrospective study,
quantitative HHV-6 PCR assays were performed
weekly on serum on 5 out of 8 patients. All of them
were positive for serumHHV-6DNA (1.15 102-8.6
103 copies/mL) very shortly before (fromday27 to day
22) or on the same day as the diagnosis of encephalitis.
Ogata et al. [18] tried to prevent HHV-6 encephalitis
Figure 2. Changes of MRI findings over time in Patient 7. FLAIR images demonstrated hyperintensities in the bilateral hippocampus at the onset of
HHV-6 encephalitis (A), as well as prominent hippocampal atrophy at 40 days (B) and 221 days (C) after the onset.
1394 Biol Blood Marrow Transplant 17:1389-1394, 2011R. Sakai et al.by a plasma HHV-6 viral load–guided preemptive ap-
proach performed once a week. However, they failed
to completely prevent this complication because 2 pa-
tients developedHHV-6 encephalopathy before detec-
tion of high-level HHV-6 DNA in plasma. They
concluded that their method cannot prevent all cases
of HHV-6 encephalopathy because of the kinetics of
the plasma HHV-6 viral load. Establishment of an op-
timal preemptive approach for HHV-6 encephalitis is
urgently needed.
In conclusion, although HHV-6 encephalitis after
HSCT is now treatable because of the development
of antiviral agents, sequelae such as persistent neuropsy-
chological disorders can adversely influence the quality-
of-life of long-term survivors. Therefore, it is necessary
to identify risk factors for HHV-6 encephalitis and
establish effective prophylaxis for this complication.ACKNOWLEDGMENTS
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